Europe Drug Delivery Devices Market By Route of Administration (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Others), By Device (Syringes, Inhalers, Patch Pumps, And Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Country, Competition, Forecast & Opportunities, 2028
Europe drug delivery devices market is expected to grow at a significant rate during the forecast period, 2024-2028. The rising adoption of advanced technology to effectively deliver drugs to the target site, along with the increasing adoption of biologics, is anticipated to augment the growth of the market. Drug delivery devices are helpful, especially in the case of patients who are unable to consume the medication through the oral route. Moreover, surging research & development activities to develop various new drugs which are effective in the treatment of several diseases are likely to positively impact the growth of the market during the forecast period. Rising investments by the public, as well as private sectors are propelling the growth of the market. Also, ease in getting FDA approvals is further expected to bolster the growth of the market over the next few years. The growing burden of chronic diseases as well as the large patient pool in the country, are surging the demand for drug delivery devices. For instance, according to the Global Cancer Observatory, in 2020, over 530,000 patients were diagnosed with breast cancer each year and accounting for approximately 29% of all cancers in women in Europe. In addition, the increasing adoption of drug-delivery devices in home-care settings is raising the accessibility of these devices for patients. Therefore, these factors are projected to strengthen the growth of the market in the upcoming years.
Rising Burden of Chronic Diseases
Increasing incidences and prevalence of chronic diseases such as cancer, hypertension, diabetes, heart strokes, and cardiovascular diseases (CVDs), among others, among the elderly population in the country, are bolstering the growth of the market. According to the European Society of Cardiology’s 2019 report, there are over 6 million new cases of CVD in the European Union (EU) and over 11 million in Europe in total every year. In addition, the increase in the proportion of older people who are aged 60 and more in the country is facilitating the growth of the market. This is because older people are more susceptible to chronic diseases due to rising age. For instance, according to Statista data of 2021, Europe has the largest proportion of the aging population at 19%, whereas Italy has the largest elderly population share with 23.5% of the total population.
Growing Adoption of Advanced Technology
Rapid advancements in the tools and technology of the healthcare sector are projected to bolster the growth of the market. These advancements are made to make the devices more patient-friendly, accessible, and accurate. For instance, in 2021, Xeris Pharmaceuticals, Inc. obtained approval from the European Commission (EC) for an Ogluo (glucagon) pre-filled pen, which is used for the treatment of severe hypoglycemia in adults, adolescents, and children the age of 2 years and over with diabetes mellitus. In addition, several players are constantly researching new technologies and developing advanced drug-delivery devices. Therefore, propelling the growth of the market.
Market Segmentation
Europe drug delivery devices market is segmented into the route of administration, device, end-user, company, and country. Based on the route of administration, the market is divided into oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, and others. Based on the device, the market is categorized into syringes, inhalers, patch pumps, and others. Based on end users, the market is bifurcated into hospitals & clinics, ambulatory surgery centers, and others. In terms of countries, the market is segmented into Germany, France, United Kingdom, Italy, Spain, Switzerland, Netherlands, Turkey, Sweden, and Belgium.
Market Players
F. Hoffmann-La Roche Ltd, Antares Pharma, Novartis AG, 3M Company, Sulzer Ltd, Gerresheimer AG, Sanofi S.A., Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline plc. are some of the leading companies operating in the market.
Report Scope:
In this report, Europe drug delivery devices market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Europe drug delivery devices market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Rising Burden of Chronic Diseases
Increasing incidences and prevalence of chronic diseases such as cancer, hypertension, diabetes, heart strokes, and cardiovascular diseases (CVDs), among others, among the elderly population in the country, are bolstering the growth of the market. According to the European Society of Cardiology’s 2019 report, there are over 6 million new cases of CVD in the European Union (EU) and over 11 million in Europe in total every year. In addition, the increase in the proportion of older people who are aged 60 and more in the country is facilitating the growth of the market. This is because older people are more susceptible to chronic diseases due to rising age. For instance, according to Statista data of 2021, Europe has the largest proportion of the aging population at 19%, whereas Italy has the largest elderly population share with 23.5% of the total population.
Growing Adoption of Advanced Technology
Rapid advancements in the tools and technology of the healthcare sector are projected to bolster the growth of the market. These advancements are made to make the devices more patient-friendly, accessible, and accurate. For instance, in 2021, Xeris Pharmaceuticals, Inc. obtained approval from the European Commission (EC) for an Ogluo (glucagon) pre-filled pen, which is used for the treatment of severe hypoglycemia in adults, adolescents, and children the age of 2 years and over with diabetes mellitus. In addition, several players are constantly researching new technologies and developing advanced drug-delivery devices. Therefore, propelling the growth of the market.
Market Segmentation
Europe drug delivery devices market is segmented into the route of administration, device, end-user, company, and country. Based on the route of administration, the market is divided into oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, and others. Based on the device, the market is categorized into syringes, inhalers, patch pumps, and others. Based on end users, the market is bifurcated into hospitals & clinics, ambulatory surgery centers, and others. In terms of countries, the market is segmented into Germany, France, United Kingdom, Italy, Spain, Switzerland, Netherlands, Turkey, Sweden, and Belgium.
Market Players
F. Hoffmann-La Roche Ltd, Antares Pharma, Novartis AG, 3M Company, Sulzer Ltd, Gerresheimer AG, Sanofi S.A., Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline plc. are some of the leading companies operating in the market.
Report Scope:
In this report, Europe drug delivery devices market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Europe Drug Delivery Devices Market, By Route of Administration:
- Oral Drug Delivery
- Injectable Drug Deliver
- Topical Drug Delivery
- Ocular Drug Delivery
- Pulmonary Drug Delivery
- Others
- Europe Drug Delivery Devices Market, By Device:
- Syringes
- Inhalers
- Patch Pumps
- Others
- Europe Drug Delivery Devices Market, By End User:
- Hospitals & Clinics
- Ambulatory Surgery Centers
- Others
- Europe Drug Delivery Devices Market, By Country:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Switzerland
- Netherlands
- Turkey
- Sweden
- Belgium
Company Profiles: Detailed analysis of the major companies present in Europe drug delivery devices market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. EUROPE DRUG DELIVERY DEVICES MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery and Others)
5.2.2. By Device (Syringes, Inhalers, Patch Pumps, And Others)
5.2.3. By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others)
5.2.4. By Country
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Route of Administration
5.3.2. By Device
5.3.3. By End User
5.3.4. By Country
5.4. Europe: Country Analysis
5.4.1. France Drug Delivery Devices Market Outlook
5.4.1.1. Market Size & Forecast
5.4.1.1.1. By Value
5.4.1.2. Market Share & Forecast
5.4.1.2.1. By Route of Administration
5.4.1.2.2. By Device
5.4.1.2.3. By End User
5.4.2. Germany Drug Delivery Devices Market Outlook
5.4.2.1. Market Size & Forecast
5.4.2.1.1. By Value
5.4.2.2. Market Share & Forecast
5.4.2.2.1. By Route of Administration
5.4.2.2.2. By Device
5.4.2.2.3. By End User
5.4.3. United Kingdom Drug Delivery Devices Market Outlook
5.4.3.1. Market Size & Forecast
5.4.3.1.1. By Value
5.4.3.2. Market Share & Forecast
5.4.3.2.1. By Route of Administration
5.4.3.2.2. By Device
5.4.3.2.3. By End User
5.4.4. Italy Drug Delivery Devices Market Outlook
5.4.4.1. Market Size & Forecast
5.4.4.1.1. By Value
5.4.4.2. Market Share & Forecast
5.4.4.2.1. By Route of Administration
5.4.4.2.2. By Device
5.4.4.2.3. By End User
5.4.5. Spain Drug Delivery Devices Market Outlook
5.4.5.1. Market Size & Forecast
5.4.5.1.1. By Value
5.4.5.2. Market Share & Forecast
5.4.5.2.1. By Route of Administration
5.4.5.2.2. By Device
5.4.5.2.3. By End User
5.4.6. Switzerland Drug Delivery Devices Market Outlook
5.4.6.1. Market Size & Forecast
5.4.6.1.1. By Value
5.4.6.2. Market Share & Forecast
5.4.6.2.1. By Route of Administration
5.4.6.2.2. By Device
5.4.6.2.3. By End User
5.4.7. Netherlands Drug Delivery Devices Market Outlook
5.4.7.1. Market Size & Forecast
5.4.7.1.1. By Value
5.4.7.2. Market Share & Forecast
5.4.7.2.1. By Route of Administration
5.4.7.2.2. By Device
5.4.7.2.3. By End User
5.4.8. Russia Drug Delivery Devices Market Outlook
5.4.8.1. Market Size & Forecast
5.4.8.1.1. By Value
5.4.8.2. Market Share & Forecast
5.4.8.2.1. By Route of Administration
5.4.8.2.2. By Device
5.4.8.2.3. By End User
5.4.9. Sweden Drug Delivery Devices Market Outlook
5.4.9.1. Market Size & Forecast
5.4.9.1.1. By Value
5.4.9.2. Market Share & Forecast
5.4.9.2.1. By Route of Administration
5.4.9.2.2. By Device
5.4.9.2.3. By End User
5.4.10. Belgium Drug Delivery Devices Market Outlook
5.4.10.1. Market Size & Forecast
5.4.10.1.1. By Value
5.4.10.2. Market Share & Forecast
5.4.10.2.1. By Route of Administration
5.4.10.2.2. By Device
5.4.10.2.3. By End User
6. MARKET DYNAMICS
6.1. Drivers
6.2. Challenges
7. MARKET TRENDS & DEVELOPMENTS
8. COMPETITIVE LANDSCAPE
8.1. F. Hoffmann-La Roche Ltd
8.2. Antares Pharma
8.3. Novartis AG
8.4. 3M Company
8.5. Sulzer Ltd
8.6. Gerresheimer AG
8.7. Sanofi S.A.
8.8. Johnson & Johnson Services, Inc.
8.9. Bayer AG
8.10. GlaxoSmithKline plc
9. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. EUROPE DRUG DELIVERY DEVICES MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery and Others)
5.2.2. By Device (Syringes, Inhalers, Patch Pumps, And Others)
5.2.3. By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others)
5.2.4. By Country
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Route of Administration
5.3.2. By Device
5.3.3. By End User
5.3.4. By Country
5.4. Europe: Country Analysis
5.4.1. France Drug Delivery Devices Market Outlook
5.4.1.1. Market Size & Forecast
5.4.1.1.1. By Value
5.4.1.2. Market Share & Forecast
5.4.1.2.1. By Route of Administration
5.4.1.2.2. By Device
5.4.1.2.3. By End User
5.4.2. Germany Drug Delivery Devices Market Outlook
5.4.2.1. Market Size & Forecast
5.4.2.1.1. By Value
5.4.2.2. Market Share & Forecast
5.4.2.2.1. By Route of Administration
5.4.2.2.2. By Device
5.4.2.2.3. By End User
5.4.3. United Kingdom Drug Delivery Devices Market Outlook
5.4.3.1. Market Size & Forecast
5.4.3.1.1. By Value
5.4.3.2. Market Share & Forecast
5.4.3.2.1. By Route of Administration
5.4.3.2.2. By Device
5.4.3.2.3. By End User
5.4.4. Italy Drug Delivery Devices Market Outlook
5.4.4.1. Market Size & Forecast
5.4.4.1.1. By Value
5.4.4.2. Market Share & Forecast
5.4.4.2.1. By Route of Administration
5.4.4.2.2. By Device
5.4.4.2.3. By End User
5.4.5. Spain Drug Delivery Devices Market Outlook
5.4.5.1. Market Size & Forecast
5.4.5.1.1. By Value
5.4.5.2. Market Share & Forecast
5.4.5.2.1. By Route of Administration
5.4.5.2.2. By Device
5.4.5.2.3. By End User
5.4.6. Switzerland Drug Delivery Devices Market Outlook
5.4.6.1. Market Size & Forecast
5.4.6.1.1. By Value
5.4.6.2. Market Share & Forecast
5.4.6.2.1. By Route of Administration
5.4.6.2.2. By Device
5.4.6.2.3. By End User
5.4.7. Netherlands Drug Delivery Devices Market Outlook
5.4.7.1. Market Size & Forecast
5.4.7.1.1. By Value
5.4.7.2. Market Share & Forecast
5.4.7.2.1. By Route of Administration
5.4.7.2.2. By Device
5.4.7.2.3. By End User
5.4.8. Russia Drug Delivery Devices Market Outlook
5.4.8.1. Market Size & Forecast
5.4.8.1.1. By Value
5.4.8.2. Market Share & Forecast
5.4.8.2.1. By Route of Administration
5.4.8.2.2. By Device
5.4.8.2.3. By End User
5.4.9. Sweden Drug Delivery Devices Market Outlook
5.4.9.1. Market Size & Forecast
5.4.9.1.1. By Value
5.4.9.2. Market Share & Forecast
5.4.9.2.1. By Route of Administration
5.4.9.2.2. By Device
5.4.9.2.3. By End User
5.4.10. Belgium Drug Delivery Devices Market Outlook
5.4.10.1. Market Size & Forecast
5.4.10.1.1. By Value
5.4.10.2. Market Share & Forecast
5.4.10.2.1. By Route of Administration
5.4.10.2.2. By Device
5.4.10.2.3. By End User
6. MARKET DYNAMICS
6.1. Drivers
6.2. Challenges
7. MARKET TRENDS & DEVELOPMENTS
8. COMPETITIVE LANDSCAPE
8.1. F. Hoffmann-La Roche Ltd
8.2. Antares Pharma
8.3. Novartis AG
8.4. 3M Company
8.5. Sulzer Ltd
8.6. Gerresheimer AG
8.7. Sanofi S.A.
8.8. Johnson & Johnson Services, Inc.
8.9. Bayer AG
8.10. GlaxoSmithKline plc
9. STRATEGIC RECOMMENDATIONS
